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Aims Atrial fibrillation (AF) has been associated with cognitive impairment. Additionally, brain volume may be reduced in
individuals with AF. Potential causes may include cerebral micro-embolism or reduced stroke volume due to the
beat-to-beat variation in AF. The aims of this study were to measure cerebral blood flow and estimate whole brain




Blood flow in the cervical arteries was measured with phase contrast MRI and brain perfusion estimated in a large
cohort from the AGES-Reykjavik Study. Individuals were divided into three groups at the time of the MRI: persist-
ent AF, paroxysmal AF, and no history of AF. Of 2291 participants (mean age 79.5 years), 117 had persistent AF
and 78 had paroxysmal AF but were in sinus rhythm at the time of imaging AF. Those with persistent AF had lower
cholesterol and used more anti-hypertensive medication and warfarin. The three groups were similar with regard
to other cardiovascular risk factors. Those in the persistent AF group had significantly lower total cerebral blood
flow on average, 472.1 mL/min, both when compared with the paroxysmal AF group, 512.3 mL/min (P < 0.05) and
the no AF group, 541.0 mL/min (P < 0.001). Brain perfusion was lowest in the persistent AF group, 46.4 mL/100 g/
min compared with the paroxysmal AF group, 50.9 mL/100 g/min in (P < 0.05) and those with no AF, 52.8 mL/100 g/
min (P < 0.001).
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Conclusion Persistent AF decreases blood flow to the brain as well as perfusion of brain tissue compared with sinus rhythm.
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Introduction
Atrial fibrillation (AF) is an important risk factor for stroke and has
been implicated in up to a third of cases of ischaemic stroke.1 More
recently, AF has been linked to cognitive impairment and dementia.1,2,3
We have previously demonstrated that AF was associated with a
decreased brain volume in addition to decline in cognitive function,
independent of cerebral infarcts.4 Thus, AF appears to affect the brain
in more ways than by causing cerebral emboli that lead to stroke.
The association of AF and decreased brain volume in our previous
study was stronger with increased arrhythmia burden and also with
longer time from first diagnosis of AF.4 Other studies have shown AF
to be associated with specific alterations in brain morphology rather
than total brain volume but those studies had rather small cohorts
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and complete brain imaging studies had not been done on all partici-
pants.5–7 Possible mechanisms connecting AF and decreased brain
volume might include multiple micro-emboli causing small cerebral
infarcts, decreased cerebral blood flow due to beat-to-beat variation
in stroke volume, neurohumoral factors, or even changes in auto-
regulation of blood flow to the brain.
The aim of this study was to evaluate and compare measured total
cerebral blood flow in the cervical arteries (mL/min) at the level of the
skull base and estimated brain perfusion (mL/100 g brain tissue/min)
measured with magnetic resonance imaging (MRI) in individuals with
and without AF at the time of imaging. The data are from the large
population-based Age, Gene/Environment Susceptibility-Reykjavik
Study (AGES-RS).
Methods
The AGES-RS, initiated in 2002, is a multidisciplinary study that was designed
to investigate the genetic and environmental factors contributing to clinical
and subclinical disease and disability in old age, providing detailed phenotypes
related to the cardiovascular, neurocognitive, and musculoskeletal systems,
and to body composition and metabolic regulation. The study is a continu-
ation of the Reykjavik Study, a total population study of men and women
born in 1907–1935, who were residents of the greater Reykjavik area in
1967. The Reykjavik Study was a longitudinal study performed from 1967 to
1994 to collect mid-life data on cardiovascular traits. The AGES-Reykjavik
study cohort is a random recruitment of survivors from the previous
Reykjavik Study, including 5764 subjects aged 67–93 years. The current study
includes cross-sectional analysis of 3316 subjects aged 71–95years of the co-
hort from the second visit of the AGES-RS, a follow-up examination of all
surviving participants who agreed to participate, conducted in 2007–2011.
Data collection included a questionnaire, clinical examination, cognitive
testing, and imaging of the brain, musculoskeletal system, body compos-
ition, vasculature, and the heart. The study design and initial assessments of
the cohort have been described previously in more detail.8 The AGES-
Reykjavik study has been approved by the Icelandic National Bioethics
Committee, which acts as the Institutional Review Board for the Icelandic
Heart Association, and by the Institutional Review Board for the Intramural
Research Program of the National Institute on Aging, National Institute of
Health, Bethesda, MD as well as The Icelandic Data Protection Authority
(VSN-063). Informed written consent was obtained from all participants.
Definition and categorization of AF status
Participants in this current study were divided into three groups accord-
ing to presence or absence of AF at the time of a brain MRI examination
and a previous history of the arrhythmia: (i) those with AF according to a
12-lead electrocardiogram (EKG), (ii) those in sinus rhythm but with a
previous history of AF (as determined from hospital records or medical
history), and (iii) those in sinus rhythm and with no previous history of
the arrhythmia. To make the presentation of the data easier to under-
stand, the group of individuals with AF at the time of the MRI exams were
defined as persistent AF and the group with a previous history, but in
sinus rhythm at the time of imaging, as paroxysmal AF. This was done
with the understanding that the some of the former may have had parox-
ysmal AF but happened to have AF at the time of MRI.
Potential confounders
Age, sex, education level (primary/secondary/college or university),
smoking status (ever smoker/former smoker/current smoker), and alco-
hol consumption (g/week) were assessed by questionnaire. Body mass
index was calculated from measured height and weight. Hypertension
was defined as self-reported doctor’s diagnosis, use of hypertensive medi-
cation or measured systolic blood pressure >_140 mmHg systolic or dia-
stolic blood pressure >_90 mmHg. Myocardial infarction was defined as
self-reported history of myocardial infarction or evidence on EKG of pos-
sible or probable myocardial infarction and coronary heart disease was
defined as prevalent disease using hospital data pertaining to diagnosis of
myocardial infarction, hospital operations including percutaneous translu-
minal coronary angioplasty and coronary artery bypass surgery. The diag-
nosis of heart failure was based on hospital discharge diagnosis codes
from all hospitals in Reykjavik. Hypercholesterolaemia was defined as
total cholesterol level >6.6 mmol/L. Diabetes mellitus type 2 was defined
as a self-reported doctor’s diagnosis, use of diabetes medication or fasting
blood glucose >7 mmol/L. At the time of data collection, warfarin was the
only anticoagulant used for stroke prevention in Iceland. Depressive
symptoms were classified as a score of 5 or higher on the 15-item
Geriatric Depression Scale and cognitive impairment was classified as 23
points or lower on the mini-mental state examination (MMSE) and 17 or
lower on digit symbol substitution test (DSST). Stroke was determined
using hospital data and coronary artery calcium was calculated using
the Agatston method from computed tomography examination of the
coronary arteries performed on a Siemens Somatom Sensation 4 multi-
detector CT scanner (Siemens Healthcare, Erlangen, Germany) with
prospective ECG triggering. Participants with dementia and diagnosis of
heart failure were excluded.
MRI acquisition and image processing
All participants without contraindications underwent brain MRI on a 1.5-
T Signa Twinspeed system (General Electric Medical Systems, Waukesha,
WI, USA) including a phase-contrast scan for flow measurements and
anatomical imaging of the whole brain for measurement of brain volume
and estimation of brain perfusion. The AGES-Reykjavik brain MRI image
acquisition protocol has previously been described in detail.9 In brief, the
protocol included a T1-weighted three-dimensional spoiled gradient
echo sequence, a proton density/T2-weighted fast-spin echo sequence,
a T2-weighted gradient echo-type echo planar imaging sequence, and a
T2-weighted fluid-attenuated inversion recovery (FLAIR) sequence. All
images were acquired to give full brain coverage in the oblique-axial
plane. Brain tissue volumes including cerebrospinal fluid (CSF), grey mat-
ter (GM), white matter (WM), and white matter hyperintensities (WMH)
were computed with a validated automatic image post-processing
pipeline.9
What’s new?
• Individuals with persistent atrial fibrillation (AF), which has pre-
viously been associated with cognitive impairment and smaller
brain volume, had decreased total cerebral blood flow and
estimated whole brain perfusion when compared with those
in sinus rhythm.
• Those with paroxysmal AF but in sinus rhythm at the time of
brain imaging had a slight but not significant lowering of cere-
bral blood flow and estimated brain perfusion than those with
no history of the arrhythmia.
• These results suggest that lower cerebral blood flow and
lower estimated whole brain perfusion may, at least in part,
help explain previous findings of smaller brain volumes and
cognitive decline in elderly individuals with AF.
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Total brain volume (TBV) was computed in millilitres (mL) as the sum
of GM volume, WM volume, and WMH volume. The intracranial volume
was computed as the sum of TBV and CSF volume. Brain volumes in this
study were normalized to intracranial volume and presented as percent-
ages of intracranial volume (TBV/ICV * 100).
Total cerebral blood flow (mL/min) was measured using phase-
contrast MRI at the level of the skull base for flow measurement in all the
cervical arteries, both the internal carotid arteries and the basilar artery.
Estimated brain perfusion in the entire brain expressed in mL/100 g brain
tissue/min was defined as the average blood flow volume divided by the
whole brain volume assuming an average brain density of 1.05 g/mL.
More details on the acquisition and analysis of phase-contrast images, the
calculation of flow and perfusion, as well as on estimating brain perfusion
has previously been described in detail.10 The operators of the MRI sys-
tem and the MR image analysts were blinded to all clinical information on
the study participants, including the AF status of each participant.
Statistical analyses
Characteristics between groups were compared using generalized linear
models (GLM) with age and sex adjustment. The assumption of a normal
distribution of the two continuous blood flow measures was verified by
inspecting qq-plots of residuals from the regression models.
Analysis of total cerebral blood flow difference between groups was
performed using GLM with age and sex adjustment, as well as adjustment
for brain volume, and for warfarin use and use of anti-hypertensive medi-
cation. Analysis of brain perfusion was done similarly with adjustments
for warfarin use and use of anti-hypertensive medication, but adjustment
for brain volume was not necessary since the outcome was already stand-
ardized by total brain volume.
All analyses were performed using SAS System/STAT software version
9.2 (SAS Institute Inc., Cary, NC, USA). Data are presented as mean
(standard deviation) for continuous variables and as % for categorical vari-
ables. A P-value <0.05 was considered statistically significant.
Analytical sample
Survivors of the AGES-Reykjavik Study were invited for a follow-up visit.
A total of 5245 individuals from the original cohort were alive at the start
of recruitment. Reasons for not participating were death before examin-
ation (n = 520), refusal (n = 1198) or loss to follow-up (n = 211). A total
of 3316 individuals gave informed consent to match the study data to hos-
pital and private physicians’ records. Of these, 648 lacked brain MRI data,
376 individuals refused MRI imaging mainly due to claustrophobia or
physical inability to undergo the investigation and 272 were excluded be-
cause of other contraindications (mainly pacemaker). Individuals with de-
mentia (n = 180) and prevalent heart failure (n = 104) were excluded. Of
the 2384 remaining subjects, 4 did not possess EKG-data and 89 did not
have cerebral blood flow measurements, resulting in a final study sample
of 2291 individuals.
Results
Of the 2291 individuals, 117 had persistent AF and 78 had a prior his-
tory of the arrhythmia but were in sinus rhythm at the time of the
brain MRI (paroxysmal AF). The mean age of the cohort was
79.5 years, ranging from 71 to 95 years (Table 1). Compared with
those without AF and those with paroxysmal AF, participants with
persistent AF were older and more often men. They had lower meas-
ured blood pressure, lower cholesterol and used more anti-
hypertensive medication and warfarin but less aspirin. As might be
expected, stroke was significantly more common in the persistent AF
group and in the paroxysmal AF group when compared with those
with no history of the arrhythmia. Those with persistent AF were not
significantly different to the other two groups with regards to body
mass index; type 2 diabetes, self-reported hypertension, coronary ar-
tery calcium, and history of myocardial infarction or coronary artery
disease. Likewise, the persistent AF group did not differ significantly
from the other two with regard to alcohol consumption, smoking
status, or educational status and they scored similar on cognitive and
depressive measures.
Individuals with persistent AF had the smallest relative brain vol-
umes (69.3%) when compared with the paroxysmal AF group
(70.3%) and to those with no history of AF (71.7%) (Table 1).
Participants in the persistent AF group had significantly lower total
cerebral blood flow on average, 472.1 mL/min, both when compared
with the paroxysmal AF group, 512.3 mL/min (P < 0.05) and the no
AF group, 541.0 mL/min (P < 0.001) (Table 2, Figure 1A). The total
cerebral blood flow in the paroxysmal AF group was lower than
in the no AF group (P < 0.05). Adjusting for relative brain volume
(Table 2) and then warfarin use as well as use of anti-hypertensive
medication did not alter the difference between those in the persist-
ent AF group vs. the no AF group but after adjustment there was no
longer a significant difference in total cerebral blood flow between
the paroxysmal AF group and those without any previous history of
the arrhythmia (Table 2 and Figure 1B).
On average, estimated whole brain perfusion was significantly low-
est in the persistent AF group, 46.4 mL/100 g/min when compared
with the paroxysmal AF group, 50.9 mL/100 g/min in (P < 0.05)
and those with no AF, 52.8 mL/100 g/min (P < 0.001) (Table 2 and
Figure 2A). After correcting for warfarin use and use of anti-
hypertensive medication the results remained unchanged, with brain
perfusion still significantly lowest in the persistent AF group (Table 2
and Figure 2B). Estimated whole brain perfusion in those with parox-
ysmal AF was not significantly lower than in the group with no history
of the arrhythmia, neither before nor after adjustment.
Discussion
In this cross sectional study of a large cohort of elderly individuals
from the general population, persistent AF was associated with
decreased total cerebral blood flow and estimated whole brain perfu-
sion assessed by phase contrast MRI of the brain. Individuals with par-
oxysmal AF, but nevertheless in sinus rhythm at the time of imaging,
had similar cerebral blood flow and brain perfusion as those with no
history of the arrhythmia. The presence of the arrhythmia at the time
of measurement of cerebral blood flow and brain perfusion thus ap-
pears to be of key importance.
We have previously shown an association between brain volume
and AF in an elderly cohort.4 A linear trend was found between lon-
ger duration of AF and greater reduction in total brain volume sug-
gesting a cumulative effect with increasing burden of the arrhythmia.
Brain atrophy both of the grey and white matter has indeed been
associated with a decline in cognitive function.11
There are a number of possible explanations for the observed as-
sociation between reduced brain volume and AF. Those include
cerebral micro-infarcts caused by small emboli from the heart,
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Age (years) 81.2 (5.1) 79.6 (4.3) 79.4 (4.5) P < 0.001 P < 0.001 P < 0.001
Sex, % men 63.3 52.6 38.8 P < 0.001 P < 0.001 P < 0.001
Education, % primary education 12.0 20.5 20.1 P = 0.16 P = 0.07 P = 0.06
Ever smoker, former or current 49.6 57.1 47.4 P = 0.40 P = 1.00 P = 0.45
Alcohol consumption (g/week)b 6.4 (1.6–26.4) 3.2 (1.6–16.1) 3.2 (0–16.1) P = 0.91 P = 0.71 P = 0.71
Height, cm 171.6 (9.9) 169.4 (9.8) 167.0 (9.1) P < 0.01 P < 0.01 P < 0.001
Body mass index (kg/m2) 27.0 (3.9) 27.3 (4.3) 26.8 (4.3) P = 0.18 P = 0.17 P = 0.19
Hypertension 94.0 94.9 88.7 P = 0.06 P = 0.09 P = 0.11
Systolic blood pressure (mmHg) 141.3 (22.8) 142.7 (22.6) 145.3 (20.7) P < 0.05 P < 0.01 P < 0.01
Myocardial infarction 13.7 16.7 12.3 P = 0.63 P = 0.60 P = 0.57
Coronary heart disease 28.2 42.3 24.2 P < 0.01 P = 0.75 P = 0.63
Cholesterol 4.9 (1.1) 4.7 (1.1) 5.3 (1.1) P < 0.001 P < 0.01 P < 0.05
Diabetes mellitus type 2 15.4 15.4 11.7 P = 0.58 P = 0.44 P = 0.47
Anti-hypertensive medication use 84.6 91.0 69.5 P < 0.001 P < 0.001 P < 0.01
Warfarin use 67.5 33.3 2.2 P < 0.001 P < 0.001 P < 0.001
Aspirin use 31.6 51.3 42.2 P < 0.01 P < 0.01 P < 0.001
GDS scale 2.4 (1.9) 2.6 (1.9) 2.1 (2.0) P < 0.05 P = 0.24 P = 0.28
MMSE score 26.2 (2.4) 26.3 (3.7) 26.6 (2.6) P = 0.85 P = 0.67 P = 0.66
DSST score 27.4 (9.6) 29.4 (9.4) 30.6 (10.1) P = 0.30 P = 0.17 P = 0.18
Stroke 16.2 19.2 6.4 P < 0.001 P < 0.001 P < 0.01
Coronary artery calciumb 671 (197–2027) 630 (126–1974) 404 (78–1173) P = 0.57 P = 0.48 P = 0.51
Total brain volume (BV) (mL) 1073.2 (103.1) 1061.3 (109.6) 1066.1 (98.3) P = 0.09 P = 0.25 P = 0.28
Intracranial volume (ICV) (mL) 1550.7 (157.6) 1510.9 (151.6) 1490.2 (146.7) P = 0.35 P = 0.18 P = 0.18
Relative BV (%) (TBV/ICV100) 69.3 (3.6) 70.3 (4.0) 71.7 (3.8) P < 0.001 P < 0.001 P < 0.001
Data are shown as mean (standard deviation) for continuous variables and as % for categorical variables.
Persistent AF, those with atrial fibrillation (AF) at the time of imaging; paroxysmal AF, those in sinus rhythm at imaging but with a previous history of AF; no AF, those in sinus
rhythm and no history of the arrhythmia. GDS, geriatric depression scale; MMSE, mini mental-state examination; DSST, digit symbol substitution test; BV, brain volume; ICV,
intracranial volume.
aAge and sex adjusted.
bMedian and quartiles.
....................................................................................................................................................................................................................
Table 2 Total cerebral blood flow and average estimated brain perfusion
Persistent AF Paroxysmal AF No AF P-value*
Total cerebral blood flow (mL/min) 472.1 512.3 541.0 <0.001
Total cerebral blood flow (mL/min)a 482.9 520.7 542.2 <0.001
Total cerebral blood flow (mL/min)b 487.3 520.0 535.5 <0.001
Brain perfusion (mL/100 g/min) 46.4 50.9 52.8 <0.001
Brain perfusion (mL/100 g/min)c 46.7 50.7 50.7 <0.001
Persistent AF, those with atrial fibrillation (AF) at the time of imaging; paroxysmal AF, those in sinus rhythm at imaging but with a previous history of AF; no AF, those in sinus
rhythm and no history of the arrhythmia.
aAdjusted for brain volume.
bAdjusted for brain volume, use of anti-hypertensive medication and warfarin use.
cAdjusted for use of anti-hypertensive medication and warfarin use. mL/min: flow in cervical arteries in millilitres per minute; mL/100 g/min: brain perfusion in millilitres per
100 grams of brain tissue per minute.
*Difference between persistent AF and no AF.
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leading to ischaemia and brain injury and possibly even atrophy.12
However, in our previous study on AF and brain volume, there was
no significant difference in brain volumes between those who were
taking warfarin anticoagulation or not.
Another explanation could be cerebral hypo-perfusion, perhaps
related to beat-to-beat variation in stroke volume in AF. Decreased
cerebral perfusion has been associated with a reduction in both grey
and white matter although the effect may be greater on the grey mat-
ter due to higher metabolic demand.4,13 There was a stronger associ-
ation between AF and lower grey matter volume than white matter
volume in our prior study, possibly lending support to the cerebral
hypo-perfusion hypothesis. Other factors such as neurohumoral ef-
fects or even altered auto-regulation of blood flow may also be play-
ing a role.
In order to explore possible causes we undertook a study to
examine whether there was a difference in cerebral blood flow and
brain perfusion in individuals with persistent AF and individuals in
sinus rhythm. In this study individuals with AF at the time of imaging
had lower total cerebral blood flow and estimated whole brain perfu-
sion compared with those in sinus rhythm regardless of a previous
history of the arrhythmia. The adverse haemodynamic effects of hav-
ing AF while the brain was imaged thus appear to be the most im-
portant variable in this observed difference. No temporal
information was available as to when individuals in sinus rhythm at
the time of imaging, but with paroxysmal AF, had their most recent
episode of arrhythmia.
Whilst cerebral flood flow in AF is not a particularly well-studied
subject there is some clinical data to support the theory that brain
hypo-perfusion flow may occur and blood flow be diminished in AF.
In one study regional cerebral blood flow was decreased in 17
subjects with AF compared with 13 in sinus rhythm using SPECT
brain imaging, suggesting that cerebral hypo-perfusion occurred with
the arrhythmia13 and another study showed cerebral blood flow
measured with trans-cranial Doppler and by Xenon-133 inhalation
technique to be lowered during AF and increased after cardi-
oversion.14–16 A small Danish study also showed improvement of
cerebral blood flow after cardioversion for AF by injecting Xenon-133
intravenously and measuring the clearance of the isotope with a brain
scintillation detector and it has also suggested that individuals with AF
may have decreased cerebral blood flow that could be reversed.17,18
More recently AF has been shown to adversely affect haemodynamic
parameters, microcirculation, and cerebral oxygenation.19,20
In the current study individuals with persistent AF had the lowest
relative brain volume and the lowest total cerebral blood flow and
brain perfusion. However, after correction for brain volume, individ-
uals with paroxysmal AF but in sinus rhythm at the time of imaging
and those with no history of the arrhythmia still had higher cerebral
blood flow than those with persistent AF, emphasizing that a rela-
tively smaller brain did not explain lowered cerebral blood flow in in-
dividuals with the arrhythmia.
Individuals with persistent AF were similar to individuals with par-
oxysmal AF and those with no history of AF with regard to BMI, dia-
betes, cardiovascular risk factors, and coronary heart disease. They
were however older, and age is the most important factor affecting
the brain but whether the threshold for adequate cerebral flood flow
and brain perfusion may be affected by age, atherosclerosis, or spe-
cific brain functions is not known. Likewise, older brains may be more
susceptible to the effects of reduced blood flow and perfusion.
In all likelihood, the haemodynamic effects on the brain are com-





















































Figure 1 (A) Total cerebral blood flow in the cervical arteries in mL/min in the three groups. Persistent AF: those with atrial fibrillation (AF) at the
time of imaging; paroxysmal AF: those in sinus rhythm at imaging but with a previous history of AF; no AF: those in sinus rhythm and with no history
of the arrhythmia. Adjustments were made for age and sex. Persistent AF vs. paroxysmal AF: P < 0.05; persistent vs. no AF: P < 0.001; paroxysmal AF
vs. no AF: P < 0.05. (B) Total cerebral blood flow in the cervical arteries in mL/min in the three groups. Persistent AF: those with atrial fibrillation (AF)
at the time of imaging; paroxysmal AF: those in sinus rhythm at imaging but with a previous history of AF; no AF: those in sinus rhythm and with no his-
tory of the arrhythmia. Adjustments were made for age, sex, brain volume, use of anti-hypertensive medication, and warfarin use. Persistent AF vs.
paroxysmal AF: P = 0.05; persistent vs. no AF: P < 0.001; paroxysmal AF vs. no AF: P > 0.05.
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suggest that decreased cerebral blood flow may play an important
role in diminished brain volume and the decline in cognitive function
seen in individuals with AF.4,7
There have been a number of studies in recent years associating
AF and cognitive impairment in individuals both with and without
prior stroke suggesting a link between the two.5,6,21 In this current
study, we excluded people with dementia; among the relatively cog-
nitively better performers there was no difference between the
groups in cognitive function as measured by MMSE and DSST tests
(Table 1).
A clear strength of the study is the large well-defined cohort and
that brain imaging with MRI was available. The method of studying
the blood flow by phase-contrast MRI is an accurate, reliable and
highly reproducible method.22 By measuring the total cerebral blood
flow in the carotids and the basilar artery the sum of blood flowing to
the brain through the cervical arteries is directly measured.23 Phase-
contrast imaging does not however assess the perfusion of the brain
tissue directly, as first pass dynamic susceptibility contrast-enhanced
magnetic resonance perfusion imaging and dynamic contrast-
enhanced magnetic resonance perfusion imaging do, as well as the
more recently developed method of arterial spin labelling magnetic
resonance perfusion imaging. The limitations of our measurement is
that perfusion is estimated rather than directly measured in the capil-
lary bed of the brain, as would be done with arterial spin labelling and
needs to be validated.
There are some additional limitations to this study. Of the original
cohort in the AGES RS a number of individuals did not participate in
this study. The reasons for this are numerous and are detailed in the
methods section. Of the 648 individuals excluded from the study due
to missing brain MRI data individuals with AF were more common as
the main reason was inability to undergo the MRI study because of
the presence of cardiac pacemakers and other medical devices that
were felt to be a contraindication for the imaging study. Additionally
the interpretation of the study results would have benefited from
more detailed information on the AF burden of the paroxysmal
group and the date of the last AF episode.
The results also raise some important clinical questions. It would
be interesting to evaluate whether restoration of sinus rhythm in indi-
viduals with AF would lead to improved blood flow to the brain. Such
a study would have to be done in a prospective manner. Likewise a
follow-up of the cohort may be of potential value regarding cognitive
outcome over time in order to support the hypothesis that AF affects
brain volume and cognition by causing reduced blood flow to the
brain and decreased brain perfusion.
The results, while intriguing, therefore need to be validated in a
longitudinal manner, preferably with measurements of total cerebral
blood flow and brain perfusion in AF and then by repeated measure-
ments after restoration of sinus rhythm in the same individuals.
Conclusions
Atrial fibrillation was associated with decrease in total cerebral blood
flow and brain perfusion in an unselected elderly cohort. These re-
sults may, at least in part, explain the association of AF with reduced
relative brain volume and cognitive impairment. There is growing
data that AF may adversely affect the brain in other ways than by
increasing the risk of cerebral infarcts. The association between per-
sistent AF and diminished cerebral blood flow and brain perfusion
are of particular interest as the consequences may potentially influ-





















































Figure 2 (A) Total brain perfusion in mL/100 g brain tissue/min in the three groups. Persistent AF: those with atrial fibrillation (AF) at the time of
imaging; paroxysmal AF: those in sinus rhythm at imaging but with a previous history of AF; no AF: those in sinus rhythm and with no history of the ar-
rhythmia. Adjustments were made for age and sex. Persistent AF vs. paroxysmal AF: P < 0.01; persistent vs. no AF: P < 0.001; paroxysmal AF vs. no
AF: P > 0.05. (B) Total brain perfusion (mL/100 g brain tissue/min) in the three groups. Persistent AF: those with atrial fibrillation (AF) at the time of
imaging; paroxysmal AF: those in sinus rhythm at imaging but with a previous history of AF; no AF: those in sinus rhythm and with no history of the ar-
rhythmia. Adjustments were made for age, sex, use of anti-hypertensive medication and warfarin. Persistent AF vs. paroxysmal AF: P < 0.05; persistent
vs. no AF: P < 0.001; paroxysmal AF vs. no AF: P > 0.05.
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